| ²é¿´: 940 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
slshihaoľ³æ (СÓÐÃûÆø)
|
[ÇóÖú]
°ïæ·ÒëÒ»¶ÎÒ©¶¯Ñ§·ÖÎö
|
||
| Pharmacokinetic parameters were estimated from the plasma concentration-time data with non-compartment analysis. Terminal elimination rate constant (Ke) was determined by linear regression of the terminal portion of the plasma concentration-time data, and the elimination half-life (t1/2) was calculated as 0.693/ Ke. The values of area under the plasma concentration-time curve from zero to thelast plasma drug concentration (AUC0-t) were calculated by the trapezoidal rule. Extrapolation to time infinity (AUC0-¡Þ)was calculated as AUC0-t+ Ct/Ke, where Ct is the last measurable plasma concentration. Values of maximal plasma concentration (Cmax) and time to maximal concentration (Tmax) were obtained directly from the plasma concentration-time curve. The total body clearance (Cl) was calculated as dose/ AUC¡Þ. The apparent volume of distribution (Vd) was calculated as Cl/Ke. |
» ²ÂÄãϲ»¶
Çóµ÷¼Á
ÒѾÓÐ23È˻ظ´
301Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
304Çóµ÷¼Á£¨085602£¬¹ýËļ¶£¬Ò»Ö¾Ô¸985£©
ÒѾÓÐ17È˻ظ´
302·ÖÇóµ÷¼Á Ò»Ö¾Ô¸°²»Õ´óѧ085601
ÒѾÓÐ12È˻ظ´
288»·¾³×¨Ë¶,Çóµ÷²ÄÁÏ·½Ïò
ÒѾÓÐ23È˻ظ´
»·¾³×¨Ë¶µ÷¼Á
ÒѾÓÐ6È˻ظ´
22408 µ÷¼Á²ÄÁÏ
ÒѾÓÐ6È˻ظ´
285Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ19È˻ظ´

8814402
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 509
- Ó¦Öú: 18 (СѧÉú)
- ¹ó±ö: 0.381
- ½ð±Ò: 12916.1
- É¢½ð: 47
- ºì»¨: 16
- Ìû×Ó: 4183
- ÔÚÏß: 357.8Сʱ
- ³æºÅ: 1184404
- ×¢²á: 2011-01-06
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
slshihao: ½ð±Ò+5, ·ÒëEPI+1, ¡ïÓаïÖú 2012-03-27 13:10:09
°®ÓëÓêÏÂ: ½ð±Ò+1 2012-03-27 20:55:44
slshihao: ½ð±Ò+5, ¡ïÓаïÖú 2012-03-28 09:59:32
slshihao: ½ð±Ò+5, ·ÒëEPI+1, ¡ïÓаïÖú 2012-03-27 13:10:09
°®ÓëÓêÏÂ: ½ð±Ò+1 2012-03-27 20:55:44
slshihao: ½ð±Ò+5, ¡ïÓаïÖú 2012-03-28 09:59:32
| Pharmacokinetic parameters were estimated from the plasma concentration-time data with non-compartment analysis. Ò©¶¯Ñ§²ÎÊýÓÉҩʱÊý¾Ý·Ç¸ôÊÒ·ÖÎö¼ÓÒÔÆÀ¹À¡£Terminal elimination rate constant (Ke) was determined by linear regression of the terminal portion of the plasma concentration-time data, and the elimination half-life (t1/2) was calculated as 0.693/ Ke. Ò©Ê±ÇøÏßÖÕÄ©¶ÎÏßÐԻعéÈ·¶¨ÖÕÄ©Ïû³ýËٶȳ£Êý£¬²¢ÒÔ0.693/ Ke ¼ÆËãÏû³ý°ëË¥ÆÚ¡£The values of area under the plasma concentration-time curve from zero to thelast plasma drug concentration (AUC0-t) were calculated by the trapezoidal rule. ҩʱÇúÏßÏÂÃæ»ýͨ¹ýÌÝÐιæÔò¼ÆËã¡£Extrapolation to time infinity (AUC0-¡Þ)was calculated as AUC0-t+ Ct/Ke, where Ct is the last measurable plasma concentration. AUC0-¡ÞÓÉÍâÍÆ·¨¼ÆËãΪAUC0-t+ Ct/Ke £¬ÕâÀïCtÊÇ×îºóÒ»¸ö¿É²âµÄѪ½¬Ò©ÎïŨ¶È¡£Values of maximal plasma concentration (Cmax) and time to maximal concentration (Tmax) were obtained directly from the plasma concentration-time curve. ×î´óѪ½¬Ò©ÎïŨ¶ÈºÍ´ï·åʱ¼äÖ±½Ó´ÓÒ©Ê±ÇøÏß»ñµÃ¡£The total body clearance (Cl) was calculated as dose/ AUC¡Þ. ÕûÌåÇå³ýÂÊClÒÔ¼ÁÁ¿/ AUC¡Þ¼ÆËã¡£ The apparent volume of distribution (Vd) was calculated as Cl/Ke.±í¹Û·Ö²¼ÈÝ»ý¼ÆËãΪCl/Ke¡£ |
2Â¥2012-03-27 09:12:32














»Ø¸´´ËÂ¥